Steroid–induced weakness in patients with primary brain tumors

Edward Dropcho, Seng Jaw Soong

Research output: Contribution to journalArticle

89 Citations (Scopus)

Abstract

Clinically significant steroid myopathy (SM) occurred in 23 (10.6%) of 216 adult patients with primary brain tumors who received 2 or more continuous weeks of daily dexamethasone therapy. SM occurred over a wide range of peak and cumulative doses of dexamethasone as well as a wide range of periods of continuous treatment. This was not an entirely random event, however, as two-thirds of the patients developed their weakness during the 9th through the 12th week of continuous dexamethasone treatment. The risk of developing SM was significantly lower in patients taking phenytoin than in patients who were not taking anticonvulsants. The only other patient or treatment factor associated with SM was a possible direct correlation with the appearance of a cushingoid body habitus. In this retrospective review, the occurrence of SM had a significant negative impact on the quality of life of all affected individuals. As expected, patients who tolerated a reduction in their steroid dose improved, while other patients suffered the combined effects of tumor progression and worsening myopathy. Substituting a nonfluorinated glucocorticoid for dexamethasone is probably advisable if neuro-oncology patients affected by SM cannot be weaned from the steroids.

Original languageEnglish (US)
Pages (from-to)1235-1239
Number of pages5
JournalNeurology
Volume41
Issue number8
StatePublished - 1991
Externally publishedYes

Fingerprint

Brain Neoplasms
Muscular Diseases
Steroids
Dexamethasone
Brain Tumor
Phenytoin
Therapeutics
Anticonvulsants
Glucocorticoids
Quality of Life
Neoplasms

ASJC Scopus subject areas

  • Arts and Humanities (miscellaneous)
  • Clinical Neurology
  • Neuroscience(all)

Cite this

Steroid–induced weakness in patients with primary brain tumors. / Dropcho, Edward; Soong, Seng Jaw.

In: Neurology, Vol. 41, No. 8, 1991, p. 1235-1239.

Research output: Contribution to journalArticle

Dropcho, Edward ; Soong, Seng Jaw. / Steroid–induced weakness in patients with primary brain tumors. In: Neurology. 1991 ; Vol. 41, No. 8. pp. 1235-1239.
@article{bce9b8ceb88d4cbc9aedcaabdd875827,
title = "Steroid–induced weakness in patients with primary brain tumors",
abstract = "Clinically significant steroid myopathy (SM) occurred in 23 (10.6{\%}) of 216 adult patients with primary brain tumors who received 2 or more continuous weeks of daily dexamethasone therapy. SM occurred over a wide range of peak and cumulative doses of dexamethasone as well as a wide range of periods of continuous treatment. This was not an entirely random event, however, as two-thirds of the patients developed their weakness during the 9th through the 12th week of continuous dexamethasone treatment. The risk of developing SM was significantly lower in patients taking phenytoin than in patients who were not taking anticonvulsants. The only other patient or treatment factor associated with SM was a possible direct correlation with the appearance of a cushingoid body habitus. In this retrospective review, the occurrence of SM had a significant negative impact on the quality of life of all affected individuals. As expected, patients who tolerated a reduction in their steroid dose improved, while other patients suffered the combined effects of tumor progression and worsening myopathy. Substituting a nonfluorinated glucocorticoid for dexamethasone is probably advisable if neuro-oncology patients affected by SM cannot be weaned from the steroids.",
author = "Edward Dropcho and Soong, {Seng Jaw}",
year = "1991",
language = "English (US)",
volume = "41",
pages = "1235--1239",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "8",

}

TY - JOUR

T1 - Steroid–induced weakness in patients with primary brain tumors

AU - Dropcho, Edward

AU - Soong, Seng Jaw

PY - 1991

Y1 - 1991

N2 - Clinically significant steroid myopathy (SM) occurred in 23 (10.6%) of 216 adult patients with primary brain tumors who received 2 or more continuous weeks of daily dexamethasone therapy. SM occurred over a wide range of peak and cumulative doses of dexamethasone as well as a wide range of periods of continuous treatment. This was not an entirely random event, however, as two-thirds of the patients developed their weakness during the 9th through the 12th week of continuous dexamethasone treatment. The risk of developing SM was significantly lower in patients taking phenytoin than in patients who were not taking anticonvulsants. The only other patient or treatment factor associated with SM was a possible direct correlation with the appearance of a cushingoid body habitus. In this retrospective review, the occurrence of SM had a significant negative impact on the quality of life of all affected individuals. As expected, patients who tolerated a reduction in their steroid dose improved, while other patients suffered the combined effects of tumor progression and worsening myopathy. Substituting a nonfluorinated glucocorticoid for dexamethasone is probably advisable if neuro-oncology patients affected by SM cannot be weaned from the steroids.

AB - Clinically significant steroid myopathy (SM) occurred in 23 (10.6%) of 216 adult patients with primary brain tumors who received 2 or more continuous weeks of daily dexamethasone therapy. SM occurred over a wide range of peak and cumulative doses of dexamethasone as well as a wide range of periods of continuous treatment. This was not an entirely random event, however, as two-thirds of the patients developed their weakness during the 9th through the 12th week of continuous dexamethasone treatment. The risk of developing SM was significantly lower in patients taking phenytoin than in patients who were not taking anticonvulsants. The only other patient or treatment factor associated with SM was a possible direct correlation with the appearance of a cushingoid body habitus. In this retrospective review, the occurrence of SM had a significant negative impact on the quality of life of all affected individuals. As expected, patients who tolerated a reduction in their steroid dose improved, while other patients suffered the combined effects of tumor progression and worsening myopathy. Substituting a nonfluorinated glucocorticoid for dexamethasone is probably advisable if neuro-oncology patients affected by SM cannot be weaned from the steroids.

UR - http://www.scopus.com/inward/record.url?scp=0025800020&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025800020&partnerID=8YFLogxK

M3 - Article

VL - 41

SP - 1235

EP - 1239

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 8

ER -